Claims for Patent: 9,975,852

Summary for Patent: 9,975,852

Title:	Quinoline sulfonyl derivatives and uses thereof
Abstract:	The present disclosure relates to quinoline sulfonyl compounds, compositions comprising these compounds and their use, in particular for the treatment of cancer. In particular, the present disclosure includes compounds of Formula (I), and compositions and uses thereof: ##STR00001##
Inventor(s):	Lee; Hoyun (Sudbury, CA), Solomon; Viswas Raja (Tamilnadu, IN), Pundir; Sheetal (Sudbury, CA)
Assignee:	Health Sciences North Research Institute (Sudbury, Ontario, CA)
Application Number:	14/772,701
Patent Claims:	1. A compound, wherein the compound is: 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline, methyl 3-(4-(7-chloroquinolin-4-yl)piperazin-1-ylsulfonyl)thiophene-2-carboxylat- e, 7-chloro-4-(4-(biphenylsulfonyl)piperazin-1-yl)quinoline, 5-(4-(7-chloroquinolin-4-yl)piperazin-1-ylsulfonyl)-N,N-dimethylnaphthale- n-1-amine, 7-chloro-4-(4-(2,4-dichlorophenylsulfonyl)piperazin-1-yl)quinol- ine, 4-[4-(3-nitro-benzenesulfonyl)-piperazin-1-yl]-7-trifluoromethylquino- line, 4-[4-(4-chloro-benzenesulfonyl)-piperazin-1-yl]-7-trifluoromethylqui- noline, 4-[4-(toluene-4-sulfonyl)-piperazin-1-yl]-7-trifluoromethylquinoli- ne, 4-[4-(biphenyl-4-sulfonyl)-piperazin-1-yl]-7-trifluoromethylquinoline, 4-[4-(2,4-dichloro-benzenesulfony)-piperazin-1-yl]-7-trifluoromethyl-quin- oline, 4-(4-methanesufonyl-piperazin-1-yl)-7-trifluoromethyl-quinoline, 4-[4-(2,4-dinitro-benzenesulfonyl)-piperazin-1-yl]-7-trifluoromethyl-quin- oline, dimethyl-{5-[4-(7-trifluoromethyl-quinolin-4-yl)piperazine-1-sulfon- yl]-naphthalen-1-yl}-amine, or 3-[4-(7-trifluoromethyl-quinolin-4-yl)-piperazine-1-sulfonyl]thiophene-2-- carboxylic acid methyl ester, or a pharmaceutically acceptable salt or solvate thereof. 2. A pharmaceutical composition comprising one or more compounds according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier. 3. A method of treating a subject with cancer, the method comprising administering a compound, or a pharmaceutically acceptable salt or solvate thereof as defined in claim 1 or a pharmaceutical composition as defined in claim 2, to the subject, wherein the cancer is breast cancer, lymphoma, cervical cancer or brain cancer. 4. The method according to claim 3, wherein the compound or pharmaceutically acceptable salt thereof or the pharmaceutical composition is administered to the subject in combination with an anti-cancer agent. 5. The method according to claim 4, wherein the anti-cancer agent is selected from Bortezomib, paclitaxel, Monastrol, Vinca, VX-680, ZM447439, Hesperidin, temozolomide, Nocodazole, Bevacizumab, Cetuximab, Geftinib, Trastuzumab, Tipifarnib, CCI-779, Ly294002, Sunitinib maleate, API-1, and Akt1/2 inhibitor. 6. The method according to claim 3, wherein the subject is a human. 7. The compound according to claim 1, wherein the compound is 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline, or a pharmaceutically acceptable salt or solvate thereof. 8. The pharmaceutical composition according to claim 2, wherein the compound is 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline, or a pharmaceutically acceptable salt or solvate thereof. 9. The method according to claim 3, wherein the method comprises administering 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline, or a pharmaceutically acceptable salt or solvate thereof to the subject. 10. The method according to claim 4, wherein the anti-cancer agent is ionizing radiation. 11. The compound according to claim 1, wherein the compound is 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline. 12. The pharmaceutical composition according to claim 2, wherein the compound is 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline. 13. The method according to claim 9, wherein the method comprises administering 7-chloro-4-(4-(2,4-dinitrophenylsulfonyl)piperazin-1-yl)quinoline to the subject. 14. The method according to claim 13, wherein the compound is administered to the subject in combination with an anti-cancer agent. 15. The method according to claim 5, wherein the anti-cancer agent is paclitaxel or bortezomib. 16. The method according to claim 14, wherein the anti-cancer agent is paclitaxel or bortezomib. 17. The method according to claim 15, wherein the cancer is breast cancer.

Details for Patent 9,975,852

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998		2034-02-18
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017		2034-02-18
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	February 12, 2004		2034-02-18
Eli Lilly And Company	ERBITUX	cetuximab	Injection	125084	March 28, 2007		2034-02-18
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2034-02-18
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	February 28, 2019		2034-02-18